Sleep Treatments

CBT-I: The Protocol Doctors Now Prescribe First

Cognitive Behavioral Therapy for Insomnia is no longer a niche alternative — it's the standard of care. A complete guide to the five components, how treatment works, and how to access it.

By Eleanor Hayes·March 3, 2025·10 min read·Reviewed by Dr. Alyssa Park, PhD, Behavioral Sleep Medicine

CBT-I: The Protocol Doctors Now Prescribe First — Photograph for Sleep Editorial.

The prescription pad used to come out quickly when a patient reported persistent insomnia. The conversation was brief: difficulty sleeping, prescription written, next patient. This pattern — deeply ingrained in how primary care managed sleep complaints for decades — is changing, and the change is not a matter of fashion or administrative preference. It reflects a formal shift in clinical guidelines backed by the strongest evidence in sleep medicine.

CBT-I is now the treatment that doctors are specifically directed to recommend first for chronic insomnia. The American College of Physicians' 2016 clinical practice guideline makes this explicit: "We recommend that all adult patients receive Cognitive Behavioral Therapy for Insomnia (CBT-I) as the initial treatment for chronic insomnia disorder." The recommendation carries a grade A classification — the highest level of recommendation strength — based on systematic review of the available evidence. Understanding why this shift happened, what the protocol actually involves, and what it means for patients seeking help for chronic sleep problems is essential context for anyone navigating the current treatment landscape.

The Evidence That Drove the Guidelines

The shift in clinical guidelines did not happen because of a single dramatic study but because of an accumulation of evidence that reached a point where the pharmacological-first approach became clinically indefensible. Several key findings converged.

Efficacy: Multiple meta-analyses synthesizing results from dozens of randomized controlled trials confirmed that CBT-I produces large, statistically significant, and clinically meaningful improvements in sleep onset latency, wake after sleep onset, sleep efficiency, and insomnia severity. Effect sizes in the meta-analyses are consistently large — larger, in most analyses, than the effect sizes for pharmacological comparators.

Durability: The most clinically compelling finding is the temporal pattern of outcomes. CBT-I gains do not plateau at post-treatment; they are maintained and often continue to improve at six-month and twelve-month follow-up. No sleep medication produces comparable durability after discontinuation. The 2015 Trauer meta-analysis in the Annals of Internal Medicine — one of the papers most directly cited in the ACP guideline — documented precisely this pattern: large post-treatment effects sustained across all follow-up time points.

Safety: CBT-I has no pharmacological adverse effects. The behavioral prescriptions produce transient fatigue during the sleep restriction phase — an expected and temporary consequence of the mechanism — but carry none of the risks associated with chronic sleep medication use: tolerance, physical dependence, rebound insomnia, cognitive impairment, fall risk in older adults, or the complex sleep behaviors now carrying black box FDA warnings for Z-drugs.

The combination of strong efficacy, superior durability, and an advantageous safety profile provided the evidence basis for the guideline shift. The question was not whether CBT-I worked better than medication over time — that was established. The question was whether the clinical system could make CBT-I accessible enough to be the default first recommendation, not a theoretical ideal reserved for the minority with access to a sleep specialist.

What the Protocol Actually Prescribes

Describing CBT-I as a "protocol" implies a level of procedural specificity that distinguishes it from generic therapeutic conversations about sleep. This specificity is real and is part of what makes CBT-I the evidence-based treatment rather than the many variations of "behavioral" or "non-pharmacological" sleep advice that do not carry the same evidence base.

A complete CBT-I course includes five discrete components, each targeting a specific maintaining factor of insomnia. Sleep restriction is the most powerful and most counterintuitive: it prescribes a specific sleep window — a bedtime and wake time — calculated from the patient's sleep diary to match their actual sleep time. The initial window is intentionally shorter than current time in bed, building homeostatic sleep pressure that consolidates fragmented sleep. The window is adjusted weekly based on sleep efficiency, extending as efficiency rises above 85 percent.

Stimulus control prescribes specific behavioral rules for the sleep environment: bed only for sleep, leave the bed if awake after approximately 20 minutes, consistent daily wake time regardless of sleep quality the previous night. These rules extinguish the conditioned association between bed and wakefulness that develops through months of anxious sleeplessness in bed.

Cognitive restructuring identifies and challenges the specific maladaptive beliefs about sleep that generate performance anxiety and physiological arousal at bedtime: catastrophic predictions about the consequences of poor sleep, unrealistic beliefs about sleep requirements, and attribution of daily functioning entirely to the previous night's sleep quality. The cognitive component uses standard CBT techniques — thought records, evidence examination, belief revision — applied specifically to the content of sleep-related cognitions.

Relaxation training addresses the physiological arousal component, providing tools — progressive muscle relaxation, diaphragmatic breathing — for reducing somatic tension and activating the parasympathetic nervous system before sleep. Sleep hygiene education provides the environmental and behavioral foundation: consistent sleep environment, caffeine and alcohol management, light and temperature optimization.

How the Protocol Is Delivered

Standard CBT-I is delivered over four to eight sessions with a trained clinician. Each session focuses on a different component or set of components, with the sleep restriction prescription and stimulus control rules introduced in the first or second session and then refined throughout the course based on sleep diary data. The patient maintains a daily sleep diary throughout, providing the data needed to calculate and adjust the sleep restriction window each week.

The time-limited nature of CBT-I is clinically and practically important. Unlike long-term therapy that continues indefinitely, a CBT-I course has a defined endpoint — typically eight sessions. At the end of the course, the patient has a complete set of behavioral skills and a personalized understanding of their sleep system. The treatment is designed to be completed and then no longer needed for daily maintenance, with the skills available for deployment if future insomnia episodes occur.

Telehealth delivery of CBT-I has expanded access significantly since the pandemic. Many CBT-I trained clinicians now offer video-based sessions, eliminating the geographic barrier that previously limited access to sleep centers. The Society of Behavioral Sleep Medicine maintains a practitioner directory at behavioralsleep.org that includes practitioners offering telehealth services.

The Access Problem and Digital Solutions

The most significant implementation challenge for the guideline shift is the fundamental scarcity of CBT-I trained practitioners. The U.S. has an estimated 30 to 40 million people with chronic insomnia and a few thousand CBT-I trained clinicians. This arithmetic makes universal first-line access to in-person CBT-I impossible with current workforce constraints.

Digital CBT-I programs have emerged as the most scalable response to this access problem. Multiple randomized controlled trials have now established that digital delivery of CBT-I produces outcomes comparable to therapist-delivered CBT-I for uncomplicated chronic insomnia. The FDA has cleared one digital CBT-I program (Somryst) as a prescription digital therapeutic, and several consumer-facing programs (Sleepio, Sleep Reset, and others) deliver the full evidence-based protocol through digital platforms at accessible price points.

The clinical community's embrace of digital CBT-I is pragmatic rather than ideological. The choice in most primary care encounters is not between in-person CBT-I and a digital program — it is between a digital program and a prescription, because in-person CBT-I is simply not available to most patients on a clinically useful timeline. In this context, digital CBT-I is not a compromise but the most evidence-based accessible option available.

What This Means for Patients

The practical implication for anyone presenting to a physician with chronic insomnia is that the guideline-concordant recommendation is CBT-I first, medication second. If your physician reaches for the prescription pad without discussing behavioral treatment, it is now clinically appropriate to ask about CBT-I — either a referral to a CBT-I practitioner, a telehealth option, or a recommendation of a specific evidence-based digital program.

The population most likely to benefit from this shift in awareness is the large group of people who have been managing insomnia with sleep medication for months or years and want a pathway to either reducing medication or eliminating it. CBT-I — whether in-person or digital — is the evidence-based tool for this transition, providing the behavioral infrastructure for medication-free sleep that medication alone cannot establish.

Frequently Asked Questions

Why did the guidelines change to recommend CBT-I first?

Because the evidence base matured to the point where CBT-I clearly produces superior long-term outcomes compared to pharmacological treatment: equal or better short-term efficacy, significantly better durability at one-year follow-up, and no adverse effects from the treatment itself. The 2016 American College of Physicians guideline reflected this evidence with a Grade A recommendation — the highest strength — for CBT-I as the first-line treatment.

Can I ask my doctor for CBT-I instead of medication?

Yes, and you should if medication is offered as a first step for chronic insomnia. Ask specifically about CBT-I referrals, telehealth CBT-I options, or evidence-based digital programs. Bringing knowledge of the ACP guideline recommendation to the conversation can be helpful framing for requesting the guideline-concordant treatment.

What does a typical CBT-I session involve?

A typical CBT-I session reviews sleep diary data from the previous week, adjusts the sleep restriction window if criteria are met, addresses any adherence challenges with the behavioral prescriptions, introduces or refines cognitive restructuring techniques for sleep-related beliefs, and provides any new relaxation or behavioral skills for the current phase of treatment. Sessions are structured and protocol-driven, not open-ended exploratory conversations.

How much does CBT-I cost with insurance?

In-person CBT-I is typically billed under behavioral health benefits and covered by most insurance plans with behavioral health coverage, usually at the same cost-sharing as other mental health services. Prior authorization may be required. Digital programs like Somryst can be prescribed and covered through medical benefits. Consumer digital programs range from $30 to $150 per month and may be covered through employer health benefit programs. Contact your insurer directly to determine coverage specifics.

The Role of Primary Care in Expanding CBT-I Access

Primary care physicians see the overwhelming majority of people with chronic insomnia before any specialist is ever consulted. This makes primary care both the bottleneck and the most important leverage point for expanding access to evidence-based insomnia treatment. Training primary care physicians to recognize when insomnia is behavioral versus physiological, to refer appropriately to digital CBT-I programs, and to frame CBT-I as the guideline-recommended treatment rather than an afterthought behind medication is an achievable and high-impact clinical education goal.

Several health systems have piloted CBT-I integration into primary care workflows through brief practitioner training combined with digital program referral pathways. The evidence from these implementations is encouraging: when primary care physicians are equipped to recommend a specific, named digital CBT-I program and explain why it is the first-line treatment, patient uptake is substantially higher than when the recommendation is vague ("you might try some behavioral strategies"). Specificity and clinical endorsement matter for motivating patients to engage with a treatment that requires more effort than swallowing a pill.

The practical next step for patients who want CBT-I but have not been offered it: ask your primary care physician specifically whether CBT-I is appropriate for your insomnia, and ask for a recommendation of a specific program or provider. The guideline-concordant answer is yes, and a specific recommendation should follow.

The shift from medication-first to CBT-I-first in insomnia management represents one of the cleaner examples of evidence-based guideline reform translating into patient benefit. Understanding this shift — and using it to advocate for guideline-concordant care — is a practical tool for anyone navigating the healthcare system with chronic insomnia.

Put This Protocol into Practice

If the evidence for CBT-I has convinced you to try it, Sleep Reset is one of the most accessible entry points available. The program delivers an individualized sleep window prescription calculated from your own diary data, stimulus control coaching, cognitive restructuring support, and a personal sleep coach who provides daily accountability — the complete protocol described in this article, packaged for self-guided use without a specialist referral.

Disclosure

Sleep Editorial is an independent publication. This article was reported and written without compensation from any product or service mentioned. Sleep Editorial does not provide medical advice; consult a qualified clinician for diagnosis and treatment.